HomeCompareRBGPF vs ABBV

RBGPF vs ABBV: Dividend Comparison 2026

RBGPF yields 4.37% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $50.3K in total portfolio value
10 years
RBGPF
RBGPF
● Live price
4.37%
Share price
$66.55
Annual div
$2.91
5Y div CAGR
23.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52.0K
Annual income
$7,903.50
Full RBGPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RBGPF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRBGPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RBGPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RBGPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RBGPF
Annual income on $10K today (after 15% tax)
$371.68/yr
After 10yr DRIP, annual income (after tax)
$6,717.97/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $14,338.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RBGPF + ABBV for your $10,000?

RBGPF: 50%ABBV: 50%
100% ABBV50/50100% RBGPF
Portfolio after 10yr
$77.2K
Annual income
$16,337.63/yr
Blended yield
21.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RBGPF
Analyst Ratings
1
Hold
1
Sell
Consensus: Hold
Altman Z
3.6
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RBGPF buys
0
ABBV buys
0
No recent congressional trades found for RBGPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRBGPFABBV
Forward yield4.37%3.06%
Annual dividend / share$2.91$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR23.2%40.6%
Portfolio after 10y$52.0K$102.3K
Annual income after 10y$7,903.50$24,771.77
Total dividends collected$27.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: RBGPF vs ABBV ($10,000, DRIP)

YearRBGPF PortfolioRBGPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,239$538.72$11,550$430.00$311.00ABBV
2$12,723$697.12$13,472$627.96$749.00ABBV
3$14,522$908.64$15,906$926.08$1.4KABBV
4$16,732$1,194.16$19,071$1,382.55$2.3KABBV
5$19,488$1,584.27$23,302$2,095.81$3.8KABBV
6$22,977$2,124.53$29,150$3,237.93$6.2KABBV
7$27,469$2,884.10$37,536$5,121.41$10.1KABBV
8$33,362$3,970.05$50,079$8,338.38$16.7KABBV
9$41,249$5,551.75$69,753$14,065.80$28.5KABBV
10$52,040$7,903.50$102,337$24,771.77$50.3KABBV

RBGPF vs ABBV: Complete Analysis 2026

RBGPFStock

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands. It also provides analgesics; sore throat medications; and hair removal products under the Nurofen, Strepsils, and Veet brands. In addition, the company offers fragrances and devices; water softeners; home cleaning products; dish washes; toilet cleaners; disinfectants; sprays, baits, and plug-ins for pest control; stain removals; fabric washing; and other hygiene products under the Air Wick, Calgon, Cillit Bang, Finish, Harpic, Lysol, Mortein, Vanish, and Woolite brands, as well as analgesics, adult nutrition products, iron-fortified hypoallergenic baby formula, products for joint issues, and infant and toddler nutrition products, as well as vitamins, minerals, and supplements under the Biofreeze, Airborne, Mead Johnson, Move Free, Enfamil, and Nutramigen brands. Further, it provides probiotics, sore throat pain relief products, Omega products, brain health support products, cleaning and carpet cleaning products, septic tank system treatment products, cough syrups, plant-based laundry products, probiotics, and lubricants under the Digestive Advantage, Cepacol, MegaRed, Neuriva, Easy-Off, RID-X, Delsym, Botanical Origin, Bodi-Ome, and K-Y brands. The company was founded in 1819 and is headquartered in Slough, the United Kingdom.

Full RBGPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RBGPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RBGPF vs SCHDRBGPF vs JEPIRBGPF vs ORBGPF vs KORBGPF vs MAINRBGPF vs JNJRBGPF vs MRKRBGPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.